Induction of Lymphosarcoma in Sheep by Bovine Leukemia Virus23

Clicks: 190
ID: 268506
1981
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Newborn sheep inoculated with phytohemagglutinin (PHA)-treated short-term cultures of lymphocytes from cattle infected with bovine leukemia virus (BLV) or with a BLV-infected long-term culture of bovine leukemic lymphocytes became persistently infected with BLV. Fifty percent or more of the sheep died with histologically confirmed lymphosarcomas. Cytogenetic studies of representative cases demonstrated that the tumors did not result from the progressive growth of neoplastic lymphocytes in the inoculum but rather from the neoplastic transformation of the recipient's lymphoid cells. Neither BLV infection nor lymphosarcoma was observed in control uninoculated sheep or in sheep given injections of PHA-treated cultures of lymphocytes from BLV-free cows. The virus recovered from the tumorous sheep was indistinguishable from BLV morphologically, antigenically, and biologically, and its reverse transcriptase had the same cation preference and immunologic properties as the BLV enzyme. Persistent BLV infection and lymphosarcoma were also observed in a group of sheep inoculated neonatally with BLV-containing cell-free culture supernatants. These results extend previous observations on the high susceptibility of sheep to BLV infection and provide definitive evidence that BLV is a tumor-inducing virus.
Reference Key
graves1981journalinduction Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Simon J. Kenyon,Jorge F. Ferrer,Richard A. Mcfeely,Donald C. Graves;Simon J. Kenyon;Jorge F. Ferrer;Richard A. Mcfeely;Donald C. Graves;
Journal journal of the national cancer institute
Year 1981
DOI
10.1093/jnci/67.5.1157
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.